IL-15 delays suppression and fails to promote immune reconstitution in virally suppressed chronically SIV-infected macaques

Blood. 2011 Sep 1;118(9):2520-9. doi: 10.1182/blood-2011-05-351155. Epub 2011 Jul 14.

Abstract

Human immunodeficiency virus (HIV) infection is characterized by a progressive loss of memory CD4(+) T cells in multiple tissues, especially at mucosal surfaces where most of these cells reside. Although antiretroviral therapy (ART) suppresses viral replication and promotes the recovery of peripheral CD4(+) T cells, HIV-infected patients fail to fully reconstitute the CD4(+) T-cell pool at mucosal sites. IL-15 has been shown to preferentially expand memory-phenotype T cells and promote their migration to nonlymphoid tissues. Here we examined IL-15 treatment in combination with highly active ART in chronically SIV-infected rhesus macaques and found that IL-15 delayed viral suppression and failed to enhance ART-induced total and antigen-specific CD4(+) T-cell reconstitution at mucosal and lymphoid sites. IL-15 was able to induce the transient proliferation of SIV-specific, CMV-specific, and total memory CD8(+) T cells, but not of SIV-specific or total CD4(+) T cells. Moreover, upon treatment interruption, macaques receiving combined IL-15+ART lost CD4(+) T cells faster than those receiving ART alone. These results suggest that the combination of IL-15 with highly active ART is not more efficient than ART alone in promoting CD4(+) T-cell recovery in HIV-infected individuals and may accelerate CD4+ T-cell loss after treatment interruption.

Publication types

  • Comparative Study
  • Research Support, N.I.H., Extramural
  • Research Support, N.I.H., Intramural

MeSH terms

  • Adaptive Immunity / drug effects
  • Adenine / administration & dosage
  • Adenine / analogs & derivatives*
  • Adenine / pharmacology
  • Adenine / therapeutic use
  • Animals
  • Anti-Retroviral Agents / administration & dosage
  • Anti-Retroviral Agents / pharmacology
  • Anti-Retroviral Agents / therapeutic use*
  • Antiretroviral Therapy, Highly Active
  • CD4 Lymphocyte Count
  • CD4-Positive T-Lymphocytes / drug effects*
  • CD4-Positive T-Lymphocytes / immunology
  • Deoxycytidine / administration & dosage
  • Deoxycytidine / analogs & derivatives*
  • Deoxycytidine / pharmacology
  • Deoxycytidine / therapeutic use
  • Drug Evaluation, Preclinical
  • Drug Therapy, Combination
  • Emtricitabine
  • Immunity, Mucosal / drug effects
  • Immunologic Factors / administration & dosage
  • Immunologic Factors / adverse effects
  • Immunologic Factors / pharmacology
  • Immunologic Factors / therapeutic use*
  • Immunotherapy
  • Interleukin-15 / administration & dosage
  • Interleukin-15 / adverse effects
  • Interleukin-15 / pharmacology
  • Interleukin-15 / therapeutic use*
  • Lymphocyte Activation
  • Lymphoid Tissue / immunology
  • Lymphoid Tissue / pathology
  • Macaca mulatta
  • Mucous Membrane / immunology
  • Mucous Membrane / pathology
  • Organophosphonates / administration & dosage
  • Organophosphonates / pharmacology
  • Organophosphonates / therapeutic use*
  • Pyrrolidinones / administration & dosage
  • Pyrrolidinones / pharmacology
  • Pyrrolidinones / therapeutic use*
  • Raltegravir Potassium
  • Random Allocation
  • Simian Acquired Immunodeficiency Syndrome / immunology*
  • Tenofovir
  • Treatment Failure
  • Viral Load

Substances

  • Anti-Retroviral Agents
  • Immunologic Factors
  • Interleukin-15
  • Organophosphonates
  • Pyrrolidinones
  • Deoxycytidine
  • Raltegravir Potassium
  • Tenofovir
  • Emtricitabine
  • Adenine